To include your compound in the COVID-19 Resource Center, submit it here.
Data from 34 chemotherapy-refractory patients in the dose-escalation and expansion stages of an open-label, U.S. Phase Ib/II trial
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury